MedTrace Logo

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

NCT00099736 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 696

Last updated 2017-08-22

No results posted yet for this study

Summary

The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.

Conditions

  • Kidney Transplantation

Interventions

DRUG

FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids

FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids

DRUG

FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids

FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids

DRUG

MMF 2 g + full-dose Neoral (FDN) + corticosteroids

mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-07
Primary Completion
2005-09-19
Completion
2005-09-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00099736 on ClinicalTrials.gov